DCM
LRMR icon

Difesa Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Difesa Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,550
Closed -$111K – 248
2022
Q3 		$111K Hold
34,550
– – 0.06% 106
2022
Q2 		$68K Sell
34,550
-17,500
-34% -$51.7K 0.04% 127
2022
Q1 		$211K Sell
52,050
-400
-0.8% -$2.62K 0.11% 116
2021
Q4 		$566K Buy
+52,450
New +$583K 0.38% 72

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Difesa Capital Management's LRMR Position: Q4 2022 in Review

Difesa Capital Management sold out of Larimar Therapeutics (LRMR) in Q4 2022, closing a stake of 34,550 shares — an estimated $111K sold.

Difesa Capital Management first reported a position in LRMR in Q4 2021 and held it in 4 quarters. The position peaked at $566K in Q4 2021. 48 funds tracked by Wall St. Rank hold LRMR as of Q4 2022.

  • Difesa Capital Management reported no remaining Larimar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Difesa Capital Management sold 34,550 Larimar Therapeutics shares in Q4 2022, an estimated $111K.
  • Difesa Capital Management first reported a position in Larimar Therapeutics in Q4 2021 and held it in 4 quarters.
  • Difesa Capital Management's Larimar Therapeutics position peaked at $566K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2022.

Based on Difesa Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.